Astec LifeSciences · NSE: ASTEC · BSE: 533138
Q3 FY21 results · Oct–Dec 2020
Astec LifeSciences reported revenue from operations of ₹116.01 crore (down 7.1% from Q3 FY20) and net profit of ₹7.06 crore (down 41.9% from Q3 FY20) for Q3 FY21 (Oct–Dec 2020), on a consolidated basis.
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 116.01 | 124.83 | −7.1% | 155.00 | −25.2% |
| Other income | 3.27 | 3.93 | −16.8% | 1.85 | +77.3% |
| Total income | 119.28 | 128.76 | −7.4% | 156.85 | −24.0% |
| Profit before tax | 11.28 | 15.61 | −27.8% | 23.88 | −52.8% |
| Net profit for the period | 7.06 | 12.17 | −41.9% | 17.85 | −60.4% |
| Attributable to shareholders of the company | 7.06 | 12.16 | −42.0% | 17.85 | −60.5% |
| EPS, basic (₹) | 3.61 | 6.22 | −42.0% | 9.12 | −60.4% |
| Net margin (%) | 6.1 | 9.7 | 11.5 |
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 116.01 | 124.83 | −7.1% | 155.00 | −25.2% |
| Other income | 3.27 | 3.93 | −16.8% | 1.59 | +105.2% |
| Total income | 119.28 | 128.76 | −7.4% | 156.60 | −23.8% |
| Profit before tax | 11.25 | 15.59 | −27.8% | 23.55 | −52.2% |
| Net profit for the period | 7.05 | 12.15 | −42.0% | 17.53 | −59.8% |
| EPS, basic (₹) | 3.60 | 6.21 | −42.0% | 8.96 | −59.8% |
| Net margin (%) | 6.1 | 9.7 | 11.3 |
Consolidated
- Filed with BSE
- 27 Jan 2021, 08:54 IST
- Board meeting
- 25 Jan 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 27 Jan 2021, 08:54 IST
- Board meeting
- 25 Jan 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE